Utility of a fluorescent probing strategy for designing a distinctive chemically mutagenized reaction for the determination of an antiepileptic agent; topiramate

In many experimental applications, fluorescent probes (fluorophores or just fluors) have replaced more traditional methods because of their adaptability, sensitivity, and quantifiability. The target analyte molecule (Topiramate) does not include any fluorogenic or chromophoric groups; hence it has no fluorescence in its native state or light absorptive power when exposed to ultraviolet light, thus; it is impossible to analyze it directly and must be undergone chemical mutagenicity in its molecular structure. This phenomenon can be achieved through fluorescent probing or labeling with tagging reagent. Consequently, the current analytical methodology depends on the fluorescence probe development via the ninhydrin reagent's utility to birth a condensed fluorescent derivative that can be tracked fluorimetrically. The final product was monitored at λem 482 nm after excitation at λex 381 nm. Under appropriate conditions, topiramate's primary amine group can condense with ninhydrin (β-diketone) and phenylacetaldehyde in a buffered solution. A new, green, feasible, and selective fluorometric strategy for topiramate assay has been presented in this work. The method offers linearity at a topiramate concentration range of 0.5 – 8 μg mL−1. The method's quantum yield was rated, and the validation parameters were examined following the International Council for Harmonisation (ICH) rules. Finally, the proposed probe was efficiently employed in the topiramate testing in the batched powder and available dosage form with high accuracy, and there was no significant effect with the existence of excipients. The findings indicate an impressive alignment with the reference documented method, showing no major variations in precision and accuracy.